Functional Scaffold Transplantation Combined With Epidural Electrical Stimulation for Spinal Cord Injury Repair

October 31, 2019 updated by: Jianwu Dai, Chinese Academy of Sciences

Safety and Efficacy of Functional Neural Regeneration Collagen Scaffold Transplantation Combined With Epidural Electrical Stimulation for Spinal Cord Injury Repair

The study is designed to assess the role of functional neural regeneration collagen scaffold transplantation combined with epidural electrical stimulation in spinal cord injury patients.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

9

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Tianjin, China, 300162
        • Recruiting
        • Affiliated Hospital of Logistics Universtiy of CAPF
        • Contact:
          • Fengwu Tang
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

The enrolled participants are divided into three categories:

  1. Participants had complete functional scaffold transplantation in previous study and had motor functional recovery
  2. Participants With Acute Complete SCI: (1) Classification ASIA A, occurring within past 14 days; (2) Completely spinal cord injury at neurological level C4- T12/L1; (3) No serious complications
  3. Participants With Chronic Complete SCI: (1) Classification ASIA A, greater than 6 months post injury and no significant further improvement within past 3 months; (2) Completely spinal cord injury at neurological level C4- T12/L1; (3) Peripheral nervous system in good condition; (4) No serious complications

Inclusion Criteria For All The Participants

  1. Men or non-pregnant women, 18-60 years old
  2. Ability and willingness to regular visit to hospital and follow up during the protocol Procedures
  3. Accompanied by a family member
  4. Signed informed consent

Exclusion Criteria:

  1. Obvious muscle atrophy or fibrosis
  2. Decline in peripheral nerve function
  3. A current diagnosis of diseases affecting spinal cord injury recovery or rehabilitation training (e.g., brain injury, cerebral hemorrhage, cognitive impairment, other central nervous system diseases)
  4. Having serious health problems, (e.g., cardiovascular disease, diabetes, autoimmune diseases, tumors or severe hypertension) or serious complications (e.g. severe bedsores, pulmonary infection, respiratory disorders)
  5. Pregnancy or lactation
  6. History of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders
  7. No family member accompany or can not get in touch with family members
  8. Poor compliance, difficult to complete the study
  9. Any other conditions that might increase the risk of participants or interfere with the clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Epidural Electrical Stimulation
Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
Experimental: Functional scaffold & Epidural Electrical Stimulation
Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and Tolerability assessed by Adverse Events
Time Frame: Up to 6 months
Proportion of patients with postoperative infections and serious adverse events (SAEs) will be assessed by long term follow-up
Up to 6 months
Change in ASIA Impairment Scale
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
American Spinal Injury Association Impairment Scale of A, B, C, D or E will be assessed before and after transplantation.
Baseline, 1, 3 , 6, 12 and 24 months post-treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in ASIA motor score
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Functional Independence Measure (FIM)
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Somatosensory Evoked Potentials (SSEP) monitoring
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Motor Evoked Potentials (MEP) monitoring
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Changes at the Transplantation Site in Spinal Cord by Magnetic Resonance Imaging (MRI)
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Walking Speed
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Stride length
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Baseline, 1, 3 , 6, 12 and 24 months post-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2019

Primary Completion (Anticipated)

December 1, 2021

Study Completion (Anticipated)

December 1, 2021

Study Registration Dates

First Submitted

May 23, 2019

First Submitted That Met QC Criteria

May 28, 2019

First Posted (Actual)

May 29, 2019

Study Record Updates

Last Update Posted (Actual)

November 1, 2019

Last Update Submitted That Met QC Criteria

October 31, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • CAS-XDA-EESCI/IGDB

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.